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Abstract
A variety of proteases have been implicated in prostate cancer (PC) bone metastasis, but the individual contribu-
tions of these enzymes remain unclear. Urokinase-type plasminogen activator (uPA), a serine protease, can acti-
vate plasminogen and stimulate signaling events on binding its receptor uPAR. In the present study, we
investigated the functional role of PC cell–associated uPA in intraosseous tumor growth and bone matrix degra-
dation. Using a severe combined immunodeficient–human mouse model, we found that PC3 cells were the major
source of uPA in the experimental bone tumor. Injection of uPA-silenced PC3 cells in bone xenografts resulted in
significant reduction of bone tumor burdens and protection of trabecular bones from destruction. The suppressed
tumor growth was associated with the level of uPA expression but not with its activity. An increase in the expres-
sion of PAI-1, the endogenous uPA inhibitor, was found during in vitro tumor-stromal interactions. Up-regulation of
PAI-1 in bone stromal cells and preosteoclasts/osteoblasts was due to soluble factor(s) released by PC cells, and
the enhanced PAI-1 expression in turn stimulated PC cell migration. Our results indicate that both tumor-derived
uPA and tumor-stroma–induced PAI-1 play important roles in intraosseous metastatic PC growth through regula-
tion of a uPA–uPAR–PAI-1 axis by autocrine/paracrine mechanisms.
Neoplasia (2008) 10, 439–449
Introduction
Bone metastasis is the most common complication that significantly
contributes to the mortality in prostate cancer (PC) patients, with no
curative treatment of the advanced disease. Once disseminated to the
bone, the metastatic prostate cancer cells interact with resident cells,
and an enhanced expression and activity of proteases that degrade
bone matrix and activate growth factors for cancer cell proliferation
is frequently observed. This osteolytic response is a prerequisite for
the generation of the osteoblastic lesions usually found in PC patients
with skeletal metastasis [1,2]. Different proteases such as matrix
metalloproteinases and cathepsins have been implicated in PC bone
metastasis based on our previous studies [3–6]. Another important
protease, urokinase plasminogen activator (uPA) was also reported
to be correlated with prostatic malignancy and PC invasion [7,8].
In PC patients, uPA expression was found to be higher in bone me-
tastases than in primary tumors [9]. Moreover, PC patients with skele-
tal metastasis showed high levels of circulating uPA [10,11].
The uPA system consists of uPA, its receptor (uPAR), plasmino-
gen, and plasminogen activator inhibitors (PAIs). uPA is secreted as a
zymogen (pro-uPA), and activation of pro-uPA is accelerated by its
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binding to uPAR [12]. The active uPA catalyzes the conversion of
plasminogen to plasmin, which in turn degrades a variety of matrix
proteins because of its broad spectrum of substrate specificities. In
addition to the proteolytic activity of uPA in the enzymatic cascade,
the binding of uPA to uPAR also results in signaling events leading to
angiogenesis [13], chemotaxis [14], cell adhesion [15], and cell pro-
liferation [16]. The multifaceted properties of uPA have made itself a
versatile regulator of tumor metastasis at different stages and there-
fore a potential therapeutic target. The activity and turnover of uPA
are regulated by another member of the system, PAI-1, which is the
primary endogenous inhibitor of uPA. According to its inhibitory
function for uPA, PAI-1 was originally predicted to suppress cancer
proliferation and metastasis. However, a growing body of evidence
has shown that high levels of PAI-1 indicate a poor prognosis for sur-
vival in some human cancers [17–19]. Additionally, host-produced
PAI-1 was found to be an important tumor-promoting factor in an
experimental mouse model [20].
Despite the clinical reports that described the association between
uPA expression and skeletal metastases in PC patients, the functional
contribution of tumor-derived uPA in bone metastasis has not been
addressed. In the present study, we carried out in vivo and in vitro
experiments to investigate the impact of uPA silencing on the growth
of human PC cells within human bone xenografts and tumor-
associated bone responses. We demonstrated that down-regulation
of tumor-derived uPA significantly reduced PC3 bone tumor burden
and protected trabecular bone from destruction. Interestingly, we also
showed that tumor-stromal interactions induced the expression of
PAI-1, which was responsible for an enhanced cancer cell migration.
Our data suggest that tumor-derived uPA is one of the dominant
factors facilitating metastatic osseous cancer growth.
Materials and Methods
Cell Lines and Stable Transfections
PC3, an androgen-independent cell line derived from a bone me-
tastasis of human prostate adenocarcinoma [21], was purchased from
American Type Culture Collection (ATCC, Manassas, VA). It was
maintained in RPMI 1640 (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with 10% FBS (Atlanta Biologicals, Lawrence-
ville, GA). An immortalized human bone marrow mesenchymal cell
(BMSC) line [22] was kindly given by Dr. Dario Campana (St Jude
Children’s Research Hospital, Memphis, TN), and maintained in
RPMI 1640 supplemented with 10% FBS and 1 nM hydrocortisone
(Sigma-Aldrich, St. Louis, MO). BMA3.1A7 (BMA), a macrophage
cell line derived from murine bone marrow (preosteoclast) [23], was
a generous gift from Dr. Kenneth Rock (Dana-Farber Cancer Insti-
tute, Boston, MA). This cell line was maintained in RPMI 1640 sup-
plemented with 10% FBS. MC3T3-E1 subclone 4 (3T3), a murine
preosteoblast cell line [24], was purchased from ATCC, and main-
tained in α-minimum essential medium (Invitrogen Life Technolo-
gies) supplemented with 10% FBS. Murine BMA and 3T3 cells were
used in our studies because of the current unavailability of human
preosteoclast/osteoblast cell lines.
A uPA small interfering RNA (siRNA)–expressing DNA insert was
constructed into the pSilencer 4.1-CMV plasmid vector (Ambion,
Austin, TX), and the selected uPA target sequence was 5′-TGA
GAG CCC TGC TGG CGC GCC-3′. The vector containing the
uPA siRNA (uPAsi)–expressing insert was amplified, purified, and se-
quenced. PC3 cells were transfected with either the uPAsi-expressing
vector or a vector expressing a scrambled siRNA (SCsi) that did not
affect uPA expression. The transfected cells were selected by geneticin
treatment, and the resistant cells were further cloned. The cloned
cells were seeded into T-75 flasks separately and cultured until about
80% confluence, followed by incubation with serum-free RPMI
for 24 hours. Total RNAs and cell lysates were prepared for reverse
transcription–polymerase chain reaction (RT-PCR), real-time PCR,
and immunoblot analysis.
Mice and Establishment of PC3 Human Bone Tumors
Five-week-old male homozygous C.B-17 scid/scid (severe combined
immunodeficient [SCID]) mice were purchased from Taconic Farms
(Germantown, NY) and allowed to acclimate for 1 week. All proce-
dures involving mice were performed according to the National Insti-
tutes of Health standards established in the Guidelines for the Care and
Use of Experimental Animals and were approved by the Animal Inves-
tigation Committee at Wayne State University School of Medicine.
Intraosseous prostate tumors were generated using the SCID-
human model, as described previously [3]. Briefly, SCID mice were
subcutaneously implanted with one quarter of human male fetal femur
obtained from elective pregnancy terminations (20 to 22 weeks of
gestation). The specimens were obtained from Advanced Bioscience
Resources (Alameda, CA) in compliance with state and federal regula-
tions. After a 4-week engraftment, the marrow of the bone xeno-
graft was injected with 20 μl of serum-free medium containing 1 ×
105 PC cells or no cells (control bone group). We first assessed uPA
expression/activity and PAI-1 expression in bone tumors formed by
inoculation of parental PC3 cells and in control bones injected only
with serum-free medium. Each of the two groups had five mice. Next,
we compared the tumor burden and bone degradation in bone tumors
generated by the injection of PC3-derived uPAsi clones and SCsi clones
(negative control expressing a SCsi), with eight animals in each group.
Preparation of Tissue Extracts and Paraffin Sections
Three weeks after the intraosseous PC3 cell injections, implanted
control bone fragments and bone tumors were harvested. Each speci-
men was longitudinally cut into two pieces. One piece was imme-
diately homogenized with 500 μl of tissue lysis buffer (150 mM
NaCl, 20 mM Tris, pH 7.5, 1% NP40, and 5 mM EDTA) in a mor-
tar (CoorsTek, Golden, CO). The homogenate was centrifuged at
10,000 rpm at 4°C for 10 minutes, and the supernatant was collected
and stored at −80°C. The other piece of tissue was fixed in 4% para-
formaldehyde overnight and decalcified for 2 weeks with 10% EDTA
(pH 6.5) in PBS. The decalcified tissue was dehydrated, infiltrated,
and paraffin-embedded. Tissue sections (5 μm) were prepared.
Cocultures and Treatment with Conditioned Media
For coculture studies, PC3 parental cells were seeded alone or to-
gether with BMSCs, BMA, or 3T3 cells (105 cells/well per cell type)
in RPMI 1640 medium supplemented with 10% FBS in 24-well
plates. Twenty-four hours later, the medium was discarded, and
the cells were washed once with PBS. Five hundred microliters of
serum-free RPMI 1640 medium were added to each well, and
the cells were cultured at 37°C for 48 hours. Conditioned media
(CM) were collected, clarified by centrifugation, and subjected to
immunoblot analysis for uPA and ELISA for PAI-1.
For experiments involving treatment with CM, PC3 and BMSCs
were seeded separately into T-75 flasks and cultured until approximately
80% confluence. The cells were then incubated with serum-free
440 uPA in Prostate Cancer Bone Metastasis Dong et al. Neoplasia Vol. 10, No. 5, 2008
RPMI for 48 hours. The CM were collected and clarified by centri-
fugation. PC3 cells and BMSCs were seeded separately into a 24-well
plate (105/well) for 24 hours and then treated with the CM collected
from the other cell type for 48 hours. Total RNA samples were pre-
pared from the cells for RT-PCR.
Semiquantitative RT-PCR and Real-time PCR
Total RNA samples were extracted from the different cells using
TRIzol reagent (Invitrogen Life Technologies), according to the manu-
facturer’s instructions. The primers used for both RT-PCR and real-
time PCR were as follows: uPA forward 5′-GTC TAC CTG GGT
CGC TCA AG-3′ and reverse 5′-CAC AGC ATT TTG GTG GTG
AC-3′; uPAR forward 5′-CTG GAG CTG GTG GAG AAA AG-3′
and reverse 5′-TGT TGC AGC ATT TCA GGA AG-3′; PAI-1 for-
ward 5′-GAA CTT CAG GAT GCA GAT G-3′ and reverse 5′-CTG
ATC ATA CCT TTT GTG TG-3′; glyceraldehyde phosphate de-
hydrogenase (GAPDH) forward 5′-AAG GTC ATC CCT GAG
CTG AA-3′ and reverse 5′-CTG ATC ATA CCT TTT GTG TG-3′.
For RT-PCR, the Reverse-iT One-Step RT-PCR kit (ABgene,
Rochester, NY) was used, and the cycle parameters were as follows:
47°C for 30 minutes for the first strand of cDNA synthesis; 94°C
for 15 minutes for reverse transcription inactivation; 94°C for 20 sec-
onds for denaturation; 60°C for 30 seconds for annealing; and 72°C
for 1 minute for extension. Amplification was carried out with 19
cycles for uPA (374-bp product) and GAPDH (271-bp product),
and 30 cycles for PAI-1 (525-bp product). PCR products were re-
solved on a 1% agarose gel by electrophoresis, and visualized by ethid-
ium bromide staining.
For real-time PCR, the Mx4000 Multiplex Quantitative PCR
System and Brilliant SYBR Green QPCR Master Mix (Stratagene,
La Jolla, CA) were used to quantitate uPAR and PAI-1 mRNA ex-
pression in PC3 clones. The experiments were performed as de-
scribed previously [25]. The relative mRNA levels of the target
genes were calculated using threshold cycles (Ct) and normalized
by internal control gene GAPDH. The formula for the calculation
was 2[target gene Ct (scrambled clone) − target gene Ct (silenced clone)]/2[GAPDH Ct
(scrambled clone) − GAPDH Ct (silenced clone)].
Immunoblot Analysis
Cell or tissue lysates obtained from different experiments were
measured for total protein concentrations using the bicinchoninic
acid assay (Pierce Chemical Company, Rockford, IL). Equal amount
of cell or tissue lysate protein was electrophoresed and transferred to
nitrocellulose membranes. The membranes were incubated with pri-
mary monoclonal antibodies against either human uPA (1 μg/ml;
EMD Chemicals Inc., San Diego, CA), human uPAR (1 μg/ml;
American Diagnostica Inc., Stamford, CT), or human cytokeratins
(1:3000; Sigma-Aldrich). The membranes were then incubated with
a secondary antibody conjugated with horseradish peroxidase (Cell
Signaling Technology, Danvers, MA). The specific bands were devel-
oped on autoradiography films by treatment of the membranes with
enhanced chemiluminescent substrate (Pierce). The membranes were
stripped and reprobed with an antibody to β-actin (1:5000; Sigma-
Aldrich), used as a loading control. To compare the relative uPA ex-
pression among different groups of PC3 bone tumors, the intensities
of specific uPA and cytokeratin bands in immunoblots were mea-
sured (total pixel count of each band) using UN-SCAN-IT software
(Silk Scientific, Orem, UT). Data were presented as a ratio of uPA
band intensities to cytokeratin band intensities.
uPA Activity Assay
uPA activity in the cell or tissue lysates was measured using the
Urokinase Activity Assay kit (EMD Chemicals Inc.), following the
manufacturer’s instructions. The assay measures only the active spe-
cies of uPA, and a standard curve was generated using recombinant
active uPA. The assay condition was optimized so that the amount
of the tissue extract or cell extract added gave rise to a uPA activity
within the linear range of the detection. Each reaction was performed
in duplicate.
PAI-1 ELISA
Human IMUBIND Tissue PAI-1 ELISA kit (American Diagnos-
tica Inc.) and Mouse PAI-1 Total Antigen ELISA Kit (Innovative Re-
search Inc., Southfield, MI) were used to measure PAI-1 expression
in CM and cell or tissue lysates, following the manufacturer’s instruc-
tions. Both kits have been shown to detect the latent and active
forms of PAI-1 and uPA-bound PAI-1 in tissue extracts and cell cul-
ture supernatants and do not cross-react with PAI-2. A standard
curve was generated using recombinant PAI-1. The assay conditions
with both kits were optimized to ensure PAI-1 detection in the linear
range. All reactions were performed in duplicates.
Immunohistochemistry
Paraffin sections prepared from control bones and PC3 bone tumors
were deparaffinized and rehydrated and were then incubated with
monoclonal antibodies against either human uPA (20 μg/ml; Ameri-
can Diagnostica Inc.) or human PAI-1 (40 μg/ml; American Diag-
nostica Inc.). After incubations with the secondary antibody, the
immunoreactivity was developed by addition of 3,3-diaminobenzidine,
and sections were counterstained with Mayer’s hematoxylin. Nega-
tive controls were slides incubated with preimmune mouse immuno-
globulin (e-Bioscience, San Diego, CA) in place of primary antibodies.
Intratumoral microvascular density (MVD) was assessed using immuno-
histochemistry as described previously [26]. Briefly, sections were in-
cubated with a monoclonal antibody against human CD34 (clone
QBEND 10; 1:50 dilution; DAKO, Carpinteria, CA) after microwave
antigen retrieval using Ag Citrus Plus Retrieval Solution (BioGenes,
San Ramon, CA). Binding of the antibody to CD34 was demonstrated
using EnVision+ System (DAKO) and diaminobenzidine. Three areas
with the most prominent CD34-positive endothelial cell clusters (hot
spots) were identified within the tumor tissue at a low magnification,
and the microvessels counted in those areas were identified at a magni-
fication of ×200.
Hematoxylin and Eosin Staining and Histomorphometry
Paraffin sections were stained with hematoxylin and eosin (H&E).
Digital photomicrographs were captured under a magnification of ×5
using a microscope (Zeiss Axioplan 2; Zeiss, Gottingen, Germany)
equipped with a software-controlled digital camera (Axiovision;
Zeiss). All ×5-microscopic fields in each longitudinal section were
analyzed. The percentage occupied by tumor and trabecular bones
in the entire section of the slide was calculated by the software.
Cell Proliferation Assay
PC3-derived SCsi and uPAsi clones were plated separately into 24-well
plates (2 × 104/ml per well) in RPMI 1640 supplemented with geneticin.
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On days 2, 4, and 6, three wells for each clone were counted using a
hematocytometer, and the mean number of the cells was calculated.
RNA Interference and Cell Motility Assay
A validated human PAI-1 siRNA (sense 5′-GCC AGA UUC AUC
AUC AAU Gtt-3′ and antisense 5′-CAU UGA UGA UGA AUC
UGG Ctc-3′) and a control siRNA were purchased from Ambion.
Bone marrow mesenchymal cells (105/well) were seeded into a
24-well plate and cultured overnight. The next day, the cells were
washed once with PBS and treated with 80 nM of either PAI-1
siRNA or control siRNA for 24 hours. To perform the cell motility
assay, siRNA-treated BMSCs growing in 24-well plates were washed
once with PBS and 500 μl of serum-free RPMI 1640 medium were
added to each well. Cell culture inserts with 8-μm pores (BD Falcon,
Treyburn, NC) containing 105 PC3 cells in 1 ml of serum-free RPMI
1640 were placed in these wells. Controls for spontaneous transmigra-
tion included inserts with PC3 cells but no BMSCs in the bottom
well. After incubation at 37°C for 16 hours, the upper face of the in-
sert membrane was wiped off using a cotton swab to remove the cells,
and the lower face of the membrane was stained with Diff-Quik kit
(Dade Behring Inc., Newark, DE). The migrated cells in the center of
the membrane were counted under a microscope at a magnification of
×400 in 10 consecutive fields, each of which equaled to 0.06 mm2.
The mean number of traversing cells was calculated.
Statistical Analysis
Data comparing differences between two groups were statistically
analyzed using unpaired Student’s t-test. Multiple comparisons were
made using one-way analysis of variance. Differences were considered
significant when P < .05.
Figure 1. uPA protein expression in representative tissue samples and CM (A); uPA activity in the tissue samples (B); PAI-1 protein
quantification in the tissue samples (C), **P < .01; and immunohistochemistry of representative samples of PC3 bone tumors (D).
Arrows indicate PC3 tumor cells; arrowheads, stromal cells and bone matrix fibers. Original magnifications, ×100 and ×400.
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Results
uPA Expression, Activity, and PAI-1 Induction in PC3
Human Bone Tumors
Tissue lysates obtained from intraosseous tumors generated by pa-
rental PC3 cell inoculation and from control bone xenografts were as-
sessed for uPA expression and activity. As shown in Figure 1A, uPA
protein was only detected in the tissue lysate prepared from PC3 bone
tumors. These results are in agreement with the data obtained from our
in vitro studies with PC3 cells and BMSCs cultured alone or together
(Figure 1A). uPA activity assay revealed corresponding uPA enzymatic
activity in the PC3 bone tumors but minimum activity in the control
bones (Figure 1B). In addition, PAI-1 expression was significantly in-
duced in the PC3 bone tumor when compared with the control bone
(P < .01) (Figure 1C ). Immunohistochemical analysis of PC3 bone tu-
mor tissues showed that uPA was predominantly expressed by PC3 tu-
mor cells, whereas PAI-1 was mainly localized to stromal cells and
matrix fibers and shown to be weaker in PC3 tumor cells (Figure 1D).
Characterization of PC3 Cells Expressing uPA Silencing RNA
Because tumor cells were the major source of uPA in the PC3
bone tumors, we applied the RNA interference technique to spe-
cifically down-regulate uPA in PC3 cells. Clones obtained by trans-
fection of PC3 cells with either the vector expressing uPA siRNA
or the vector expressing SCsi were selected, and total RNA and pro-
tein samples were prepared. RT-PCR analysis revealed a group of
PC3 clones with reduced levels of uPA mRNA expression due to
uPA silencing (uPAsi C2, C3, and C6) compared with the clone ex-
pressing SCsi (SCsi C3; Figure 2A). Immunoblot analysis further
Figure 2. Expression of uPA mRNA (A), protein (B), and enzymatic activity (C), ***P < .001 when compared with other three groups;
**P< .01 when compared with uPAsi C2 or C3; +++P< .001 when compared with uPAsi C3; expression of uPAR mRNA (D) and protein
(E) in PC3 clones, *P < .05 when compared with uPAsi C3 or C6.
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confirmed the inhibition of uPA expression in uPAsi clones at the
protein level, with decreasing intensity of the specific band from
C2 to C6 (Figure 2B). The specific activity assay showed a gradual
reduction of uPA activity in these clones consistent with their respec-
tive uPA expression (P < .001; Figure 3C ), although uPA activity in
the uPAsi clone 2 was slightly higher than that in the SCsi control
clone (Figure 2C ). Real-time PCR and immunoblot analyses of uPAsi
clones revealed a similar trend for uPAR (Figure 2, D and E ). We
also checked PAI-1 expression at both mRNA and protein levels in
the clones. As shown in Figure 3A, there was significant reduction of
PAI-1 mRNA expression in uPAsi clones when compared with that
in the SCsi clone (P < .001). Results from ELISA displayed an iden-
tical pattern of PAI-1 expression at the protein level (Figure 3B).
To evaluate the growth effect of uPA silencing on the PC3 clones,
we performed a cell proliferation assay. As shown in Figure 3C, the
proliferation rate of uPAsi PC3 cells was retarded by uPA down-
regulation and correlated with the level of uPA expression.
Inhibition of PC3 Bone Tumor Proliferation and Trabecular
Bone Degradation By uPA Silencing
To investigate the role of tumor-derived uPA in PC bone tumor
growth and subsequent bone turnover, we carried out an in vivo ex-
periment using the uPA silenced PC3 clones. Human fetal bone frag-
ments were implanted into SCID mice, and the uPAsi or SCsi PC3
cells were injected into the implanted human fetal bone xenografts
4 weeks later. Three weeks after PC3 cell inoculation, the fetal bone
fragments were harvested and processed for histologic and biochemi-
cal studies. The bone xenografts injected with the SCsi PC3 clone
exhibited aggressive bone tumor growth and trabecular bone degra-
dation by H&E staining. On the contrary, the bones injected with
PC3 clones silenced for uPA showed smaller tumors and reduced
matrix degradation (Figure 4A). Immunoblot analysis of tissue lysates
from individual bone xenografts using the uPA monoclonal antibody
revealed lower uPA expression in the uPAsi clones than that in the
SCsi clone (Figure 4B). The epithelial marker cytokeratin was also
detected in these samples and used as an indicator of PC3 tumor
cells. The intensities of specific cytokeratin bands in the SCsi bone
tumor group were relatively higher than that in the uPAsi groups. To
compare the relative uPA expression in the bone tumors among dif-
ferent groups, the specific bands from both uPA and cytokeratin were
scanned, and the ratios of uPA to cytokeratin intensities were calcu-
lated. As shown in Figure 4B, the uPA expression was dramatically
reduced in uPAsi C3 and C6 bone tumors when compared to that in
SCsi bone tumors. We further performed histomorphometrical analy-
sis to quantify the bone tumor burden and the area occupied by tra-
beculae. As shown in Figure 5A, uPA silencing significantly reduced
Figure 3. mRNA expression (A) and protein quantification (B) of PAI-1 in PC3 clones, ***P < .001 when compared with other three
groups; and proliferation rates of PC3 clones (C).
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the size of PC3 bone tumors when compared with that generated by
the SCsi clone (P < .01 between uPAsi C2 and SCsi; and P < .001
between uPAsi C3 or C6 and SCsi). This inhibitory effect on tumor
growth was associated with reduced levels of uPA expression, as the
clones expressing lower levels of uPA generated smaller tumors. Sub-
sequently, the degradation of trabecular bones in the uPAsi PC3 bone
tumors was less severe than that in the SCsi PC3 bone tumors (P <
.05, between uPAsi C3 or C6 and SCsi; Figure 5B). These data suggest
that the protective effect on trabecular bones was likely to result di-
rectly from uPA silencing. To investigate the effect of uPA silencing
on intraosseous tumor angiogenesis, we assessed the MVD in the bone
tumors from each group. The results obtained showed no significant
differences in MVD among the groups (data not shown).
Up-regulation of PAI-1 By In Vitro PC Cell–Bone
Cell Interactions
As shown earlier in Figure 1C, PAI-1 expression was significantly
higher in PC3 bone tumors than in control bone xenografts. To
Figure 4. (A) H&E staining of PC3 bone tumor tissues obtained from human fetal bone xenografts injected with PC3 clones (representative
samples). Original magnification, ×100. Arrows and clear arrowheads point tumor cells and bone trabeculae, respectively. (B) Relative ex-
pression of uPA and cytokeratin in tissue lysates prepared from the PC clone bone tumors. Data are presented as mean ± SE ratio of uPA
band intensities to cytokeratin band intensities.
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explore whether this result could be due to PAI-1 induction, we con-
ducted in vitro coculture experiments of PC3 and BMSCs. As shown
in Figure 6A, the interaction of PC3 cell with bone stromal cells led
to a dramatic increase in PAI-1 expression (P < .001). Similarly, co-
cultures of PC3 cells with either mouse 3T3 preosteoblasts or mouse
BMA preosteoclasts also enhanced mouse PAI-1 expression (P < .001
and P < .05, respectively; Figure 6B). We then collected PC3 or
BMSC CM and applied the CM from one cell type to the culture
of the other cell type. The results showed that only the CM from
PC3 cells stimulated PAI-1 mRNA expression in BMSC, whereas
the CM from BMSC did not change PAI-1 mRNA expression in
PC3 cells (Figure 6C ).
Stimulation of PC3 Cell Migration By PAI-1 from BMSCs
Next, we tested the effect of induced PAI-1 from BMSC on PC3
cell motility. BMSCs were treated with the specific human PAI-1
siRNA for 24 hours, which confirmed down-regulation of PAI-1
mRNA (Figure 7A). In vitro assays were used to quantitate PC3
cell motility across the filter with 8-μm pores toward BMSCs. We
found that BMSCs stimulated the migration of PC3 cells when com-
pared to the spontaneous PC3 cell migration (with no BMSC in the
bottom well), and the induction of PC3 cell motility was almost
completely abolished when BMSCs were pretreated with the specific
PAI-1 siRNA (P < .01; Figure 7B).
Discussion
Overexpression of uPA has been reported in primary PC and bone
metastasis [7–9,27]. Because the precise pathologic role of tumor-
derived uPA in PC bone metastasis is still unclear, here we investi-
gated the effect of silencing PC3 uPA expression on intraosseous
tumor growth. This cell line was of choice for our study, because
it was initiated from a bone metastasis of a PC patient and it has
the highest uPA expression among the three most used PC cell lines,
namely, LNCaP, DU145, and PC3 [28,29]. Our in vivo data with
parental PC3 cells indicate that cancer cells are the major source
for uPA when they proliferate in the implanted bone. These results
were confirmed by our coculture studies using PC3 and BMSCs.
Characterization of PC3-derived transfected clones revealed an as-
sociation between uPA silencing and the reduction of uPA mRNA
and protein expression. Interestingly, uPA C2 showed even higher
uPA activity than the control PC3 clone (SCsi C3). This finding
could be potentially ascribed to different PAI-1 levels in those two
clones, as PAI-1 can bind active uPA and inhibit its activity [30].
Indeed, significant down-regulation of PAI-1 expression was revealed
by ELISA in all three uPAsi clones. Although uPAsi C2 had relatively
lower uPA expression than SCsi C3 due to siRNA silencing, its PAI-1
expression was much lower than that from SCsi C3, which led to
more free uPA molecules unbound by PAI-1 and therefore higher
uPA activity in uPAsi C2. The other two uPAsi clones also exhibited
similar reduction of PAI-1 to uPAsi C2, but their uPA expression was
substantially silenced. Therefore, the reduction of net uPA activity
in uPAsi C3 and C6 was mainly due to the reduced uPA synthesis.
Furthermore, low concentrations of uPA in uPAsi C3 and C6 might
promote binding of PAI-1, although also at very low concentrations,
to uPA/uPAR and trigger the formation of trimeric complex uPA/
uPAR/PAI-1, leading to internalization and degradation of both
uPA and PAI-1 [31].
Our in vivo silencing experiment used several uPAsi PC3 clones
with different levels of uPA down-regulation to investigate the precise
role of uPA in intraosseous PC3 tumor growth and bone matrix deg-
radation. Quantifications of tumor and trabecular bone areas by
histomorphometric analysis showed significant reduction of bone
tumor burdens and remarkable protection of trabecular bones by
uPA silencing. The use of siRNA to target uPA expression has been
reported in other experimental tumor models. For instance, intra-
peritoneal injection of a vector expressing uPA and uPAR siRNA re-
duced preestablished intracranial growth of gliomas in nude mice
[32], and intratumoral injection of a plasmid construct expressing
uPA and uPAR siRNA completely inhibited established orthotopic
PC3 tumors in immunosuppressed mice [33]. Our study differs from
those mentioned previously in that we specifically silenced uPA in
prostate cancer cells that represent the major source of this serine
protease in intraosseous tumors. Knockdown of tumor-associated
uPA was sufficient to achieve a significant reduction of intraosseous
PC growth and bone degradation in the SCID-human model of PC
skeletal metastasis. To our knowledge, this is the first study that
revealed a functional role for PC cell–derived uPA in intraosseous
tumor growth and bone turnover.
The establishment and growth of metastatic cancer cells in the
bone marrow require osteolysis for their physical expansion, and
Figure 5. Tumor burden (A) and trabecular degradation (B) in PC3
bone tumors obtained from human fetal bone xenografts injected
with PC3 clones, *P < .05 and ***P < .001, when compared with
uPAsi C6; +P < .05 and +++P < .001, when compared with uPAsi
C3; ##P < .01 when compared with SCsi C3.
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the calcium and marrow-derived growth factors released by matrix
degradation provide living supports for the metastatic cancer cell
proliferation [34]. The serine protease uPA specifically activates plas-
minogen into active plasmin, which in turn cleaves a variety of ex-
tracellular matrix substrates such as fibronectin, vitronectin, and
fibrin [35]. In addition, uPA is also involved in many biologic func-
tions, as it regulates growth factor activation, cell adhesion, chemo-
taxis, and angiogenesis [36,37]. In the current study, we found that
the in vitro proliferation rate of PC3 clones was closely associated
with uPA expression but not with uPA activity. This is further con-
firmed by our in vivo experiment that showed an association between
uPA expression and intraosseous tumor burdens, whereas uPA ac-
tivity revealed no significant changes among different groups (data
not shown). Achbarou et al. [38] found that the enzymatic activity
Figure 6. PAI-1 expression in the cocultures of PC3 cells with human BMSCs (A) or with mouse osteoclasts/osteoblasts (B), ***P< .001
when compared with the remaining groups, +++P < .001 when compared with BMA, +P < .05 when compared with 3T3; and PAI-1
mRNA expression in BMSCs treated with PC3 CM (C).
Figure 7. Expression of PAI-1 mRNA in BMSCs treated with PAI-1 siRNA (A) and PC3 cell motility assay (B), P< .01 when compared with
control siRNA-treated PC3 cells.
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of uPA promotes PC cell intravasation into the vasculature and ex-
travasation into bone tissue. However, our in vivo model is used to
study the last stage of skeletal metastasis, namely intraosseous tumor
growth, in which degradation of basement membrane might not
be necessary. At this stage, the expression of uPA, rather than its ac-
tivity, may be more important for maintaining continuous tumor
proliferation. The growth-stimulating effect of uPA on tumor cells
has been previously reported, and it was found that either applica-
tion of uPA siRNA or stable transfection of a vector expressing
uPA siRNA remarkably reduced cell growth rates of a breast cancer
cell line [39] and a hepatocellular carcinoma cell line [40]. This effect
was initiated by binding of the uPA growth factor domain to its re-
ceptor uPAR, and there was no uPA activity needed for this process
[29,41,42]. Interestingly, it was found that uPAR expression was also
regulated by uPA. Mahanivong et al. [43] demonstrated that the
introduction of uPA antisense RNA to human breast cancer cells
reduced not only uPA but also uPAR expression in these cells and
that this inhibition could be reversed by the addition of soluble
single-chain uPA to the cell culture system. Our data collected from
real-time PCR showed a concomitant down-regulation of uPAR
mRNA by uPA silencing, which was confirmed at the protein level
(uPAsi C6) by immunoblot. These findings further suggest that uPA
silencing attenuates the number of uPA-uPAR complex and therefore
reduces signaling stimulation for cell growth.
uPA is regulated at different levels for its expression and activity.
After activation, uPA activity can be inhibited by its endogenous
inhibitors. PAI-1, albeit a predominant uPA inhibitor, has been re-
ported to be overexpressed in a variety of neoplasms such as breast
[44], lung [45], colon [46], ovary [47], kidney [48], and oral [49]
cancers. Usher et al. [50] detected PAI-1 mRNA and protein expres-
sion in specimens obtained from 13 of 16 prostate cancer patients
and found the localization in fibroblast like cells. Our studies revealed
enhanced PAI-1 expression in intraosseous PC3 tumors, which was
verified by our coculture experiments. This up-regulation of PAI-1
was due to soluble factors from PC3 cells that stimulated PAI-1 gene
transcription in bone cells. Furthermore, PAI-1 expression was also
regulated by uPA because uPA silencing in PC3 cells led to reduc-
tion of PAI-1 expression at both the gene and protein levels. These
data suggest that PAI-1 expression is regulated by paracrine and auto-
crine mechanisms. We also investigated the role of PAI-1 in regula-
tion of PC cell motility. We found that soluble factors derived from
BMSCs were chemotactic for PC3 cells. Silencing PAI-1 gene in
the BMSCs by specific PAI-1 siRNA led to a significant reduction
in PC3 cell motility, indicating that PAI-1 was one of the soluble
factors that induced PC3 cell migration. A possible mechanism un-
derlying this response could be ascribed to PAI-1’s impact on cell at-
tachment [51].
In conclusion, we demonstrated that silencing uPA in PC3 cells
led to not only reduced uPA but also suppressed uPAR. These
uPA-silenced PC3 cells produced lower tumor burdens and less tra-
becular bone degradation than the SCsi PC3 control cells. These
effects were mainly due to reduced uPA expression rather than in-
hibited uPA activity. The concomitant uPAR down-regulation by
uPA silencing, together with the attenuated PAI-1 induction in
bone resident cells, may also contribute to the reduced intraosseous
tumor burden. Taken together, these results suggest that both tumor-
derived uPA and tumor-stroma–induced PAI-1 play important roles
in intraosseous metastatic PC growth through regulation of a uPA–
uPAR–PAI-1 axis by autocrine/paracrine mechanisms. Therefore,
targeting uPA may provide an effective treatment of the patients with
prostate cancer bone metastasis. Our findings in concert with our
previous studies on matrix metalloproteinase [3,4] also suggest that
although certain protease activities can be crucial for tumor-induced
osteolytic responses, expression levels of other proteases such as uPA
may have substantial impact on metastatic tumor growth.
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